Compare APVO & NISN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APVO | NISN |
|---|---|---|
| Founded | 2016 | 2005 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.7M | 19.4M |
| IPO Year | N/A | 2016 |
| Metric | APVO | NISN |
|---|---|---|
| Price | $1.07 | $3.41 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 11.6K |
| Earning Date | 11-06-2025 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.43 |
| Revenue | N/A | ★ $340,219,546.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $14.74 |
| Revenue Growth | N/A | ★ 8.05 |
| 52 Week Low | $1.04 | $3.22 |
| 52 Week High | $298.00 | $9.33 |
| Indicator | APVO | NISN |
|---|---|---|
| Relative Strength Index (RSI) | 33.47 | 31.52 |
| Support Level | $1.07 | $3.25 |
| Resistance Level | $1.41 | $3.49 |
| Average True Range (ATR) | 0.09 | 0.16 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 14.46 | 1.47 |
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
NiSun International Enterprise Development Group Co Ltd is a provider of supply chain solutions and integrated financial services. Nisun is dedicated to providing professional supply chain solutions to Chinese and foreign enterprises and financial institutions. Through its subsidiaries, it is engaged in delivering supply chain solutions, and supply chain trading services to its customers across different industries. The company also provides financial solutions to small and mid-sized enterprises within the supply chain ecosystem. Using its fintech platforms, it provides various financing options, including supply chain financing, trade financing, and receivables financing. Geographically, its operations are predominantly focused on markets within the People's Republic of China.